Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 66
Filter
1.
Leukemia ; 29(2): 290-6, 2015 Feb.
Article in English | MEDLINE | ID: mdl-24888273

ABSTRACT

Sixty-two infants with MLL gene-rearrangement-positive acute lymphoblastic leukemia (MLL-r ALL) were treated with the MLL03 protocol of the Japanese Pediatric Leukemia/Lymphoma Study Group: short-course intensive chemotherapy followed by early allogeneic hematopoietic stem cell transplantation (HSCT) within 4 months of the initial induction. The 4-year event-free survival and overall survival rates were 43.2% (95% confidence interval (CI)=30.7-55.1%) and 67.2% (53.8-77.4%), respectively. A univariate analysis showed younger age (<90 days at diagnosis), central nervous system disease and poor response to initial prednisolone therapy significantly associated with poor prognosis (P<0.05). In a multivariate analysis, younger age at diagnosis tended to be associated with poor outcome (hazard ratio=1.969; 95% CI=0.903-4.291; P=0.088). Although the strategy of early use of HSCT effectively prevented early relapse and was feasible for infants with MLL-r ALL, the fact that substantial number of patients still relapsed even though transplanted in their first remission indicates the limited efficacy of allogeneic HSCT for infants with MLL-r ALL. Considering the risk of severe late effects, indications for HSCT should be restricted to specific subgroups with poor risk factors. An alternative approach incorporating molecular-targeted drugs should be established.


Subject(s)
Gene Rearrangement , Hematopoietic Stem Cell Transplantation , Myeloid-Lymphoid Leukemia Protein/genetics , Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics , Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy , Antineoplastic Agents/therapeutic use , Child, Preschool , Disease-Free Survival , Female , Histone-Lysine N-Methyltransferase , Humans , Infant , Male , Multivariate Analysis , Neoplasm Recurrence, Local/therapy , Neoplasm, Residual , Prednisolone/therapeutic use , Prognosis , Proportional Hazards Models , Recurrence , Risk Factors , Transplantation, Homologous , Treatment Outcome
2.
Leukemia ; 24(2): 335-44, 2010 Feb.
Article in English | MEDLINE | ID: mdl-20016539

ABSTRACT

We analyzed the long-term outcomes of 1021 patients with acute lymphoblastic leukemia (ALL), enrolled in four successive clinical trials (ALL811, ALL841, ALL874 and ALL911) between 1981 and 1993. All patients received risk-adopted therapy according to leukocyte count and age at the time of diagnosis. The median follow-up durations of the four studies were 17.8 years in ALL811, 15.5 years in ALL841, 11.9 years in ALL874 and 15.8 years in ALL911. Patients' event-free survival (EFS) and overall survival (OS) rates at 12 years were 41.0 and 54.3% in ALL811, 50.2 and 60.2% in ALL841, 57.3 and 64.7% in ALL874, and 63.4 and 71.7% in ALL911, respectively. Thus, cure can become a reality for about 70% of children with ALL. There is, however, still a significant difference in survival outcomes according to risk group. Late effects were observed in 70 patients out of 834 (8.4%); hepatitis and short stature were most commonly reported. Reduction of late adverse effects for all patients and development of new treatment strategies for very-high-risk patients are major issues for upcoming trials to address.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Adolescent , Child , Child, Preschool , Combined Modality Therapy , Disease-Free Survival , Female , Follow-Up Studies , Humans , Infant , Infant, Newborn , Japan , Male , Medical Oncology/organization & administration , Precursor Cell Lymphoblastic Leukemia-Lymphoma/diagnosis , Prognosis , Remission Induction , Risk Factors , Survival Rate , Time Factors , Treatment Outcome
3.
Leuk Res ; 29(6): 625-32, 2005 Jun.
Article in English | MEDLINE | ID: mdl-15863201

ABSTRACT

We report here a retrospective analysis of 36 children with therapy-related myelodysplastic syndrome (t-MDS) diagnosed between 1990 and 1999 in Japan. Their median age was 7.7 years and the median latency period for the development of t-MDS was 38.5 months. The primary tumors were hematologic in 15 of the cases and nonhematologic in 21. Chromosomal abnormalities were detected in 32/34(94%) patients: abnormalities of chromosomes 5and/or 7 in 41% and notably, 11q23 abnormalities in 31%. The prognosis of children with t-MDS was very poor as compared to children with primary MDS (5 year survival: 16% versus 54%, p<0.0001).


Subject(s)
Combined Modality Therapy/adverse effects , Myelodysplastic Syndromes/chemically induced , Adolescent , Child , Child, Preschool , Chromosome Aberrations , Chromosomes, Human, Pair 11/genetics , Chromosomes, Human, Pair 5/genetics , Chromosomes, Human, Pair 7/genetics , Cytogenetic Analysis , Female , Humans , Japan , Male , Myelodysplastic Syndromes/diagnosis , Myelodysplastic Syndromes/genetics , Prognosis , Retrospective Studies , Sample Size , Survival Analysis , Treatment Outcome
4.
Leuk Lymphoma ; 42(3): 393-8, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11699404

ABSTRACT

To evaluate the clinical implications of CD45 expression in acute childhood lymphoblastic leukemia (ALL), we measured the CD45 expression of blast cells from 133 untreated patients with childhood B-precursor ALL (n = 118) or T-ALL (n = 15). CD45 expression (> or = 20%) was detected in all 15 cases (100%) of T-ALL, and 101 cases (86%) of B-precursor ALL. In 122 cases, the fluorescence intensity of the CD45 expression was measured as a relative value; the ratio of average linear values (RALV) of CD45 on the blasts to that on CD3-positive T-lymphocytes from the same specimen. The expression was more intense in the T-ALL cases than in the B-precursor ALL cases (RALV, mean +/- SE: T-ALL 0.230 +/- 0.04 vs. pro-B ALL 0.150 +/- 0.012/pre-B ALL 0.153 +/- 0.019, p < 0.05). However, the intensity of the CD10, CD19, CD20 and CD34 antigen immunoreactivity did not correlate with the CD45 expression. Patients with hyperdiploidy (chromosome number > 50) showed significantly lower levels of CD45 expression than patients with t(1;19) or normal karyotypes (RALV, mean +/- SE: 0.081 +/- 0.022 vs. 0.133 +/- 0.03/0.143 +/- 0.019, p < 0.05). Other clinical features such as age, gender and WBC count did not correlate with CD45 expression. The prognostic implications of CD45 expression were studied in non-high-risk (low-risk + intermediate-risk) (n = 60) and high-risk patients (n = 52) with B-precursor ALL who had been treated with the risk-directed protocol of ALL-941 trial. Although CD45 expression did not correlate with the event-free survival (EFS) of the non-high-risk patients, there was a significant correlation between the expression levels and the EFS of the high-risk patients: the 3-year EFS rate of the CD45low group (n = 26, RALV = 0.017-0.132) was 88 +/- 7% versus the CD45high group (n = 26, RALV = 0.133-0.450) at 34 +/- 24% (p < 0.05). These results show that the levels of expression of the CD45 antigen on leukemic lymphoblasts are significantly correlated with the clinical features and prognosis of childhood ALL.


Subject(s)
Antigens, CD/analysis , B-Lymphocytes/immunology , Leukocyte Common Antigens/analysis , Precursor Cell Lymphoblastic Leukemia-Lymphoma/immunology , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Asparaginase/administration & dosage , Child , Disease-Free Survival , Doxorubicin/administration & dosage , Humans , Immunophenotyping , Mercaptopurine/administration & dosage , Methotrexate/administration & dosage , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Prednisolone/administration & dosage , Prognosis , Remission Induction , Time Factors , Vincristine/administration & dosage
5.
Blood ; 97(4): 1147-9, 2001 Feb 15.
Article in English | MEDLINE | ID: mdl-11159552

ABSTRACT

Macrothrombocytopenia with leukocyte inclusions is a rare autosomal dominant platelet disorder characterized by a triad of giant platelets, thrombocytopenia, and characteristic Döhle body-like leukocyte inclusions. A previous study mapped a locus for the disease on chromosome 22q12.3-q13.2 by genome-wide linkage analysis. In addition, the complete DNA sequence of human chromosome 22 allowed a positional candidate approach, and results here indicate that the gene encoding nonmuscle myosin heavy chain-A, NMMHC-A, is mutated in this disorder. Mutations were found in 6 of 7 Japanese families studied: 3 missense mutations, a nonsense mutation, and a one-base deletion resulting in a premature termination. Immunofluorescence studies revealed that NMMHC-A distribution in neutrophils appeared to mimic the inclusion bodies. These results provide evidence for the involvement of abnormal NMMHC-A in the formation of leukocyte inclusions and also in platelet morphogenesis.


Subject(s)
Blood Platelets/pathology , Genes, Dominant , Leukocytes/ultrastructure , Molecular Motor Proteins , Mutation , Thrombocytopenia/genetics , Amino Acid Sequence , Chromosome Mapping , Chromosomes, Human, Pair 22/genetics , DNA Mutational Analysis , Female , Humans , Inclusion Bodies/ultrastructure , Japan , Male , Molecular Sequence Data , Morphogenesis , Myosin Heavy Chains/genetics , Neutrophils/chemistry , Neutrophils/ultrastructure , Pedigree , Sequence Alignment , Sequence Deletion , Sequence Homology, Amino Acid , Syndrome , Thrombocytopenia/pathology
6.
Gan To Kagaku Ryoho ; 28(13): 2049-54, 2001 Dec.
Article in Japanese | MEDLINE | ID: mdl-11791383

ABSTRACT

A Phase I trial of irinotecan hydrochloride (CPT-11) was performed to determine the maximum tolerated dose (MTD), the dose-limiting toxicities, and the incidence and severity of other toxicities in children with advanced neuroblastoma. Three children received 11 courses of CPT-11 administered as a 90-min i.v. infusion, daily for 3 days every 21 days. Doses ranged from 100 mg/m2 to 220 mg/m2. Two peaks in the total number of instances of diarrhea was observed, 25 stools at 3 days and 32 stools at 10 days. Myelosuppression was well controlled and of brief duration. One child achieved a clinical complete response (CR) and 2 had a partial response (PR). The MTD of CPT-11 administration was 180 mg/m2 for 3 days. These results indicate the usefulness of CPT-11 for the treatment of advanced neuroblastoma. Further investigation is necessary to establish its role in combination chemotherapeutic regimens.


Subject(s)
Adrenal Gland Neoplasms/drug therapy , Antineoplastic Agents, Phytogenic/therapeutic use , Camptothecin/analogs & derivatives , Camptothecin/therapeutic use , Neuroblastoma/drug therapy , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Child, Preschool , Cisplatin/administration & dosage , Cyclophosphamide/administration & dosage , Doxorubicin/administration & dosage , Drug Administration Schedule , Etoposide/administration & dosage , Female , Humans , Infant , Irinotecan
7.
Gan To Kagaku Ryoho ; 27(11): 1695-702, 2000 Oct.
Article in Japanese | MEDLINE | ID: mdl-11057320

ABSTRACT

To address the issue of salvageability in relapsed children with NHL who had all received the same frontline therapy, we retrospectively studied the treatment response and the outcome of 27 children who relapsed following the CCLSG-NHL890 protocol. The reinduction rates and 3-year survival rates (mean +/- SD) were as follows: lymphoblastic lymphoma (LB, n = 9), 44% & 17 +/- 14%; leukemia lymphoma syndrome (LLS, n = 8), 25% & 0%; large cell lymphoma (LC, n = 3) 100% & 67 +/- 27%; Burkitt's lymphoma (B, n = 7) 0% & 0%. Thus, the salvageability of LC lymphoma was good, but the outcome of Burkitt's lymphoma was very poor. CCLSG-NHL960 protocol for LB lymphomas and intensive multiagent regimens for LC lymphomas produced favorable response rates, but the effect of the high-dose Ara-C regimen for Burkitt's lymphoma was not determined. The initial stages of the disease seemed to be associated with the patient outcome: the outcome of the patients in stage IV was inferior to that of patients in stages II or III. Other clinical variables, such as relapse sites, relapse time and BM rescue did not affect the patients' outcome.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Lymphoma, Non-Hodgkin/drug therapy , Adolescent , Child , Child, Preschool , Cyclophosphamide/administration & dosage , Doxorubicin/administration & dosage , Doxorubicin/analogs & derivatives , Drug Administration Schedule , Female , Humans , Lymphoma, Non-Hodgkin/mortality , Lymphoma, Non-Hodgkin/pathology , Male , Methotrexate/administration & dosage , Prednisolone/administration & dosage , Prognosis , Recurrence , Retrospective Studies , Salvage Therapy , Survival Rate , Vincristine/administration & dosage
9.
Gan To Kagaku Ryoho ; 26(8): 1050-5, 1999 Jul.
Article in Japanese | MEDLINE | ID: mdl-10431576

ABSTRACT

In recent years, the results of treating children with advanced non-Hodgkin's lymphomas have improved markedly. Among patients with small non-cleaved cell lymphoma (both Burkitt's and Burkitt-like lymphomas according to the Revised European American Lymphoma Classification) in particular, about 80% could be cured by a short intensive polychemotherapy containing cyclophosphamide, high-dose methotrexate, and high-dose cytarabine. In contrast, standard treatment strategies for the diffuse large cell lymphomas and lymphoblastic lymphomas have yet to be established. Recent studies have shown that the treatment protocols for patients with large cell lymphomas should be determined based on both the histological and immunological classifications. Since the outcome of lymphoblastic lymphoma patients who are treated with a multi-drug regimen is less than optimal, further improvement in this therapy is needed. At the present time, the combination of bone marrow rescue with high-dose therapy is partially effective for refractory cases. To further help these patients, new strategies with allogenic stem cell transplantation to further boost the potential graft-versus-lymphoma effect appear necessary.


Subject(s)
Lymphoma, Non-Hodgkin/therapy , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Child , Combined Modality Therapy , Humans
10.
Int J Hematol ; 69(3): 206-10, 1999 Apr.
Article in English | MEDLINE | ID: mdl-10222662

ABSTRACT

This report describes the first Japanese family diagnosed with Sebastian platelet syndrome. Within this family, a 6-year-old boy and 3 family members on his paternal side demonstrated thrombocytopenia with giant platelets and inclusion bodies in granulocytes, but the additional clinical features of Alport's syndrome occurring in the Fechtner syndrome were lacking. Light microscopy and ultrastructural findings of the leukocyte inclusion bodies distinguished these patients from the May-Hegglin anomaly. This family showed consistently higher levels of platelet-associated IgG (PAIgG), while surface expression of platelet membrane glycoproteins (GPIIb/IIIa and GPIb) and plasma glycocalicin levels were within the normal range. Careful observation of the giant platelet and leukocyte inclusion bodies in blood smears may help the diagnosis of this rare disease entity.


Subject(s)
Blood Platelets/pathology , Inclusion Bodies/pathology , Thrombocytopenia/genetics , Adult , Blood Platelets/cytology , Child , Child, Preschool , Diagnosis, Differential , Female , Humans , Immunoglobulin G/analysis , Japan/epidemiology , Leukocytes/cytology , Leukocytes/pathology , Male , Middle Aged , Pedigree , Platelet Glycoprotein GPIb-IX Complex/analysis , Syndrome , Thrombocytopenia/epidemiology , Thrombocytopenia/immunology
11.
Gan To Kagaku Ryoho ; 26(5): 679-85, 1999 Apr.
Article in Japanese | MEDLINE | ID: mdl-10234300

ABSTRACT

Time-course-analysis of two apoptotic events of DNA fragmentation and delta psi m reduction revealed that delta psi m reduction preceded DNA fragmentation in U937 and Molt-4 cells treated with etoposide (ETP). DNA fragmentation and delta psi m reduction were inhibited by N-acetylcysteine (NAC) in both cell lines treated with ETP. These findings suggest that DNA fragmentation was inhibited through maintenance of delta psi m. Z-Asp-CH2-DCB, interleukin-1 beta-converting enzyme (ICE) specific inhibitor, inhibited ETP-induced DNA fragmentation and delta psi m reduction in U937 cells. This suggests that activation of ICE is an earlier event than delta psi m reduction. On the other hand, in Molt-4 cells, Z-Asp-CH2-DCB inhibited ETP-induced DNA fragmentation but not delta psi m reduction, suggesting that delta psi m reduction occurs earlier than activation of ICE.


Subject(s)
Apoptosis , Caspase 1/physiology , Mitochondria/physiology , Signal Transduction/physiology , DNA Fragmentation , Etoposide/pharmacology , Humans , Leukemia, Myeloid/pathology , Leukemia, T-Cell/pathology , Membrane Potentials , Tumor Cells, Cultured , U937 Cells
12.
Med Pediatr Oncol ; 32(4): 259-6, 1999 Apr.
Article in English | MEDLINE | ID: mdl-10102019

ABSTRACT

BACKGROUND: Prevention of central nervous system (CNS) leukemia by early introduction of therapy to this sanctuary site is an essential component of modern treatment strategy for acute lymphoblastic leukemia (ALL). However, the optimal form of preventive CNS therapy remains debatable. PROCEDURE: To address this issue, we evaluated the efficacy of CNS preventive therapy for 572 children with ALL who achieved complete remission in the Children's Cancer and Leukemia Study Group (CCLSG) ALL874 (1987-1990) and ALL911 (1991-1993) studies. They received risk-directed therapy based on age and leukocyte count. In the ALL 874 study, the non-high-risk (low-risk [LR] + intermediate risk [IR]) patients were randomly assigned to the conventional cranial irradiation (CRT) regimen (L874A and I874A) and the high-dose methotrexate (HDMTX) regimen without CRT (L874B and I874B). The former patients received 18-Gy CRT plus 3 doses of intrathecal (i.t.) MTX and the latter patients received 3 courses of HDMTX at 2 g/m2 plus 13 doses of ITMTX (L874B) or 4 courses of HDMTX at 4.5 g/m2 plus 1 dose of ITMTX (I874B). RESULTS: The 7-year probabilities (+/- SE) of CNS relapse-free survival were 97.3% +/- 2.6% (L874A, n = 41) vs. 90.3% +/- 5.3% (L874B, n = 39) (P = 0.25) in the LR patients, and 100% (I874A, n = 55) vs. 78.5% +/- 6.5% (I874B, n = 54) (P = 0.002) in the IR patients. The corresponding disease-free survival (DFS) rates were 79.4% +/- 6.5% vs. 74.4% +/- 7.3% (P = 0.62) in the LR group and 63.3% +/- 6.8% vs. 58.3% +/- 7.2% (P = 0.66) in the IR group. Thus, the HDMTX regimen could not provide better protection of CNS relapse as compared with the CRT regimen, although their overall efficacy was not significantly different. In the ALL 911 study, intensive systemic chemotherapy with extended i,t, injections of MTX plus cytarabine achieved a high CNS relapse-free survival (98% +/- 1.9% at 7 years) and a favorable DFS (85.5% +/- 5% at 7 years) in the IR patients. The patients in the high-risk (HR) group in both ALL874 and ALL911 studies received the 18-Gy or 24-Gy CRT with intensive systemic chemotherapy. Their 7-year probabilities of CNS relapse-free survival ranged from 88% to 95%, among which the T-ALL patients had a risk of CNS leukemia, which was 3-4 times higher compared with B-precursor ALL patients. CONCLUSIONS: These results indicate that long-term intrathecal CNS prophylaxis as well as appropriate systemic therapy for the non-high-risk patients can provide protection against CNS relapse equivalent to that provided by cranial irradiation.


Subject(s)
Antimetabolites, Antineoplastic/administration & dosage , Central Nervous System Neoplasms/drug therapy , Central Nervous System Neoplasms/radiotherapy , Methotrexate/administration & dosage , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology , Adolescent , Adult , Central Nervous System Neoplasms/secondary , Child , Child, Preschool , Disease-Free Survival , Drug Administration Schedule , Female , Humans , Infant , Injections, Spinal , Japan , Male , Radiotherapy, Adjuvant , Treatment Outcome
13.
Rinsho Ketsueki ; 39(11): 1092-8, 1998 Nov.
Article in Japanese | MEDLINE | ID: mdl-9866420

ABSTRACT

We report here on the preliminary treatment findings of a CCLSG NHL 960 study that was initiated in March 1996. In this study, 37 patients with non-Hodgkin's lymphoma were assigned to 4 different treatment groups according to disease stage and histology: (1) localized disease; (2) advanced disease, lymphoblastic type; (3) advanced disease, large cell type; and (4) advanced disease, Burkitt type. The first three groups received the modified protocols of the NHL 890 study. Groups 1 and 3 received COPADM induction therapy (CPM, VCR, PRD, ADR, and MTX). After achieving remission, Group 1 received only maintenance therapy consisting of alternate administration of 7 drugs, while Group 3 received additional intensification therapy with combination chemotherapy consisting of MTX and Ara-C, followed by a maintenance phase involving the administration of 9 drugs. Group 2 received COPADL induction therapy (CPM, VCR, PRD, ADR, and LASP) and consolidation/intensification therapies followed by a maintenance phase. Group 4 received short-term intensive COPADM polychemotherapy. Twelve patients with localized with localized disease (stage I-II) and 25 patients with advanced disease (stage III-IV) were enrolled in this study. Except for 2 patients in the advanced disease stages who died earlier in the course of the study, all patients remained in remission.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Lymphoma, Non-Hodgkin/drug therapy , Adolescent , Anti-Inflammatory Agents/administration & dosage , Antimetabolites, Antineoplastic/administration & dosage , Antineoplastic Agents, Alkylating/administration & dosage , Antineoplastic Agents, Hormonal/administration & dosage , Antineoplastic Agents, Phytogenic/administration & dosage , Asparaginase/administration & dosage , Burkitt Lymphoma/drug therapy , Child , Child, Preschool , Cyclophosphamide/administration & dosage , Cytarabine/administration & dosage , Daunorubicin/administration & dosage , Dexamethasone/administration & dosage , Doxorubicin/administration & dosage , Etoposide/administration & dosage , Female , Humans , Hydrocortisone/administration & dosage , Infant , Lymphoma, Large B-Cell, Diffuse/drug therapy , Male , Methotrexate/administration & dosage , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Prednisolone/administration & dosage , Remission Induction , Vincristine/administration & dosage
14.
Rinsho Ketsueki ; 39(8): 565-73, 1998 Aug.
Article in Japanese | MEDLINE | ID: mdl-9785974

ABSTRACT

To clarify the efficacy of modern intensive chemotherapy for ALL patients with unfavorable features, we compared the time to failure and initial clinical features of children who relapsed in the bone marrow or combined sites, as documented by early CCLSG studies (H811 and H851; 1981-1987) and later studies (H874 and H/HH911; 1987-1993) concerning high-risk ALL patients. In the later studies patients outcomes with new intensive regimens employing early intensification and reinduction therapy were apparently better than those of patients in the early studies with conventional regimens. When we compared the number of relapsed patients based on duration of first remission, we found that the improved outcomes for patients in the later studies were due to a decrease in the number who relapsed 7-36 months after the start of treatment (intermediate relapse), and that the percentage of those who relapsed within the first 6 months of therapy (early relapse) was higher. Patients with high initial WBC counts tended to relapse much earlier than those with low initial WBC counts. However, in the later studies, patients with high WBC counts often relapsed after the termination of therapy (late relapse). These results suggest that the intensive chemotherapy regimens used in the later studies can prevent the development of drug resistant leukemic clones, except in extremely high-risk patients likely to relapse within the first 6 months of therapy.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bone Marrow Neoplasms/etiology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Child , Child, Preschool , Female , Humans , Male , Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology , Recurrence , Risk , Time Factors
15.
Rinsho Ketsueki ; 39(4): 281-9, 1998 Apr.
Article in Japanese | MEDLINE | ID: mdl-9597895

ABSTRACT

We report here on treatment results of consecutive CCLSG NHL studies (NHL855, 1985-1989; NHL890, 1989-1996). The NHL855 protocol consisted of an induction phase of five drugs (VCR, PRD, CPM, DXR, and high-dose MTX) and a maintenance phase of 7 drugs. The probabilities of EFS at 7 years were 78% (SE, 10%) for the patients with localized disease, and 38% (SE, 7%) for those with advanced disease. In the NHL 890 protocol, the patients were assigned to two different treatment groups according to their histology and received different consolidation therapy; non-lymphoblastic subtype was treated almost identically to NHL855 while LASP and VP-16 were newly added for the lymphoblastic subtype. The 7-year EFS improved to 91% (SE, 6%) for localized disease, and 61% (SE, 6%) for advanced disease. A remarkable improvement was particularly evident for lymphoblastic type with mediastinal mass. Optional trial of high-dose sequential chemotherapy and peripheral blood progenitor cell auto grafting resulted in an unfavorable outcome. The 7-year EFS according to main histological subgroups were as follows: 84% (10%) for large cell type, 67% (11%) for Burkitt's-type, 58% (10%) for lymphoblastic type. Secondary cancer occurred in two of the 163 patients studied. Both patients were AML (M0/M4) and MLL rearrangement was detected in the M4 case.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Leukemia, Myeloid, Acute/epidemiology , Lymphoma, Non-Hodgkin/drug therapy , Neoplasms, Second Primary/epidemiology , Adolescent , Asparaginase/administration & dosage , Child , Child, Preschool , Cyclophosphamide/administration & dosage , Cytarabine/administration & dosage , Doxorubicin/administration & dosage , Etoposide/administration & dosage , Female , Follow-Up Studies , Humans , Hydrocortisone/administration & dosage , Infant , Lymphoma, Non-Hodgkin/pathology , Male , Mercaptopurine/administration & dosage , Methotrexate/administration & dosage , Prednisolone/administration & dosage , Remission Induction , Treatment Outcome , Vincristine/administration & dosage
16.
Pediatr Hematol Oncol ; 15(2): 143-55, 1998.
Article in English | MEDLINE | ID: mdl-9592841

ABSTRACT

Bcl-2 expression and its prognostic value were evaluated in 42 children with acute leukemia. The Bcl-2 expression of the leukemic blast cells was measured quantitatively by flow cytometry and was further analyzed by the simultaneous immunostaining of Bcl-2 with the surface membrane antigens, DNA, Ki-67 antigen. All of the cases showed a consistent expression of Bcl-2 protein; virtually all leukemic lymphoblasts were Bcl-2 positive. Although the expression of Bcl-2 varied widely from 7 to 80 x 10(3) MESF units, no significant difference was found in the mean value between the patients with acute lymphoblastic leukemia and those with acute myeloblastic leukemia. In more than half of the patients with AML, intraclonal heterogeneity of Bcl-2 expression was observed. The expression of Bcl-2 showed no apparent fluctuations during the different phases of the cell cycle. However, the proportion of Bcl-2-positive and -negative cells during the cell cycle was different between ALL and AML patients. In the ALL patients, few Bcl-2-negative cells were detected only in the GI phase, whereas in the AML patients Bcl-2-negative cells were detected in the S and G2/M phases, as well as in the G1 phase. No apparent difference was found in Bcl-2 expression between the Ki-67-negative noncycling population and the Ki-67-positive cycling population. Of the clinical features of these patients, only CD34 expression in the ALL patients was associated with high levels of Bcl-2 expression. In the 28 untreated cases of ALL, high expression of Bcl-2 was not an unfavorable factor for the outcome of this disease.


Subject(s)
Leukemia, Myeloid, Acute/diagnosis , Leukemia, Myeloid, Acute/metabolism , Precursor Cell Lymphoblastic Leukemia-Lymphoma/diagnosis , Precursor Cell Lymphoblastic Leukemia-Lymphoma/metabolism , Proto-Oncogene Proteins c-bcl-2/biosynthesis , Adolescent , Bone Marrow Cells/physiology , Cell Cycle , Child , Child, Preschool , DNA/analysis , Disease-Free Survival , Female , Flow Cytometry , Gene Expression , Humans , Immunoglobulin Fab Fragments/analysis , Immunophenotyping , Infant , Leukemia, Myeloid, Acute/genetics , Leukocyte Count , Leukocytes/immunology , Male , Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics , Prognosis , Proto-Oncogene Proteins c-bcl-2/genetics
17.
Rinsho Ketsueki ; 38(8): 647-56, 1997 Aug.
Article in Japanese | MEDLINE | ID: mdl-9311270

ABSTRACT

We report on the leukemic cell karyotype of 180 children with acute myeloblastic leukemia (AML). They were treated by the protocols of chemotherapy for the Children's Cancer and Leukemia Study Group (CCLSG) in the last decade. Of 132 cases with adequate banding analysis, 24.2% had normal karyotype, 21.2% had miscellaneous clonal abnormalities and 54.6% were classified into known cytogenetic subgroups: t(8;21) (n = 35), t(15;17) (n = 23), inv (16) (n = 6), t(11q23;V) (n = 6), -7/7q-(n = 2). Each karyotype was closely correlated with a particular FAB subtype such as t(8;21) in M2, t(15;17) in M3, inv (16) in M4, t(11q23;V) in M5. In the M1+M2 group, although patients with t(8;21) had favorable clinical features such as low WBC counts and less frequent lymphadenopathy, their treatment outcome was not significantly better than those of patients with a normal karyotype (3-year EFS: 58 +/- 11% vs. 47 +/- 12%). Patients with miscellaneous chromosomal abnormalities had a significantly shorter EFS (22% +/- 10%) (p < 0.05) than those with t(8;21) or normal karyotype. In M4+M5 group, 2-year EFS of patients with inv (16) (40 + 30%) was longer than that of patients with normal karyotype (25 +/- 19%), and t(11q23;V) or miscellaneous chromosomal abnormalities (0 +/- 25%). These results suggest that cytogenetic data may be useful for risk-based treatment assignments for children with AML.


Subject(s)
Chromosome Aberrations , Leukemia, Myeloid, Acute/genetics , Adolescent , Adult , Child , Child, Preschool , Female , Humans , Infant , Karyotyping , Male , Prognosis
18.
Int J Hematol ; 66(1): 79-88, 1997 Jul.
Article in English | MEDLINE | ID: mdl-9220663

ABSTRACT

To investigate how chemotherapy agents interact with the leukemic cell death pathway, we examined apoptosis of human lymphoblastic leukemia cells (Nalm-6 and Molt-4) treated with various anticancer drugs (etoposide (VP-16), camptothecin (CPT), adriamycin (ADR), cytosine arabinoside (Ara-C), methotrexate (MTX), 6 mercaptopurine (6MP), cyclophosphamide (CPM), vincristine (VCR) and prednisolone (PRD)) by flow cytometric procedures. The proportion of apoptotic cells was estimated from the presence of cells with a fractional DNA content in the DNA histograms after the incubation of drug-treated cells with a DNA extraction buffer. Treatment with Ara-C, CPT, VP-16 and ADR resulted in rapid apoptosis with 40-60% apoptotic cells by 8 h. Treatment with MTX, VCR, 6MP and PRD induced no apparent apoptosis until 12 h, but further treatments with these drugs resulted in apoptosis with 50% (MTX), 20-30% (6MP and VCR) and 5-10% (PRD) apoptotic cells, respectively, at 24 h. CPM induced apoptosis with 10-20% apoptotic cells at 10(-6) M, but higher doses (> 10(-5) M) caused a rapid cell death by necrosis. The cell cycle position of apoptotic cells was assessed by the terminal deoxynucleotidyl transferase (TdT) assay of DNA strand breaks combined with DNA staining. MTX, Ara-C, CPT, VP-16 and ADR preferentially induced apoptosis in the S phase. PRD and 6MP induced apoptosis in the G1 phase and G1 + S phases, respectively. CPM showed no cell cycle phase specificity. These findings suggested that the susceptibility of cells to apoptosis was not the sole determinant of cellular sensitivity of cytotoxic drugs.


Subject(s)
Antineoplastic Agents/pharmacology , Apoptosis/drug effects , Leukemia, Lymphoid/pathology , DNA Damage/drug effects , Flow Cytometry , Humans , Tumor Cells, Cultured
19.
Int J Hematol ; 66(1): 103-10, 1997 Jul.
Article in English | MEDLINE | ID: mdl-9220666

ABSTRACT

Treatment outcome and prognostic factors were evaluated in 152 children with acute myeloblastic leukemia (AML) treated on three consecutive protocols (ANLL 861, 8912, 9205) of the Children's Cancer Leukemia Study Group (CCLSG, Japan). In the ANLL 9205 protocol, anthracycline was used with a continuous infusion of cytosine arabinoside, followed by an intensive sequential post remission chemotherapy of short duration. Forty-two of these 46 patients (91.3%) achieved complete remission, and 58.8% of these patients projected a 3-year disease-free survival. These results were apparently superior to those obtained with the ANLL 861 and 8912 protocols, which used conventional doses of multiple drugs followed by a moderate post remission chemotherapy of long duration. This favorable response with the ANLL 9205 protocol was attributed mainly to the high induction rate of patients with the M4 and M5 FAB subtypes, as compared to those in the previous two protocols (93.3% in ANLL 9205 vs. 57.9% in ANLL 861 + 8912; P < 0.05). The ANLL 861 and 8912 protocols, an older age (> or = 8 years), higher WBC counts (> or = 10 x 10(9)/1) and all predicted an increased risk of relapse and decreased the survival following univariate analysis (P < 0.05). An older age and high WBC count continued to predict an increased risk of relapse in multivariate analyses: patients with an age > 8 years and WBC counts > 10 x 10(9)/1 had a 4.5 times higher risk of relapse than patients without these adverse features.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Leukemia, Myeloid, Acute , Adolescent , Child , Child, Preschool , Female , Humans , Infant , Leukemia, Myeloid, Acute/drug therapy , Leukemia, Myeloid, Acute/physiopathology , Male , Prognosis , Treatment Outcome
20.
Rinsho Ketsueki ; 38(7): 561-5, 1997 Jul.
Article in Japanese | MEDLINE | ID: mdl-9267157

ABSTRACT

Prognostic value of cellular DNA content was evaluated in 189 children with acute lymphoblastic leukemia. Treatment outcome of the three different DNA index (DI) groups (Group A, DI = 1.0 vs. Group B, DI 1.01-1.15 vs. Group C, DI > or = 1.16) was compared between the two treatment risk groups (standard-risk and high-risk groups) stratified by the initial leukocyte count and age. In the standard-risk group, these groups had 10-year event free survival (EFS) rate (SE) of 62% (6%), 40% (21%) and 87% (6%), respectively (p < 0.05). In the high risk group, they had 10-year EFS rate of 30% (5%), 33% (27%) and 60% (19%), respectively (p < 0.01). Use of the DI, leukocyte count and age may be sufficient to distinguish the patients with an extremely low risk of failing to the standard ALL therapy from the patients with a relatively high-risk of treatment failure.


Subject(s)
DNA, Neoplasm/analysis , Precursor Cell Lymphoblastic Leukemia-Lymphoma/mortality , Child , Child, Preschool , Humans , Infant , Prognosis , Survival Rate , Treatment Failure
SELECTION OF CITATIONS
SEARCH DETAIL
...